Willingness to Vaccinate Against COVID-19 in the U.S.: Representative Longitudinal Evidence From April to October 2020 by Daly, Michael & Robinson, Eric
ARTICLE IN PRESS© 2021 American Journal of Preventive Medicine. Publis








hed by Elsevier Inc.
ttp://creativecommons.org/licWillingness to Vaccinate Against COVID-19 in the
U.S.: Representative Longitudinal Evidence
From April to October 2020Michael Daly, PhD,1 Eric Robinson, PhD2Introduction: Vaccines against COVID-19 have been developed in unprecedented time. However,
the effectiveness of any vaccine is dictated by the proportion of the population willing to be vacci-
nated. This observational population-based study examines intentions to be vaccinated against
COVID-19 throughout the pandemic.
Methods: In November 2020, longitudinal data from a nationally representative sample of
7,547 U.S. adults enrolled in the Understanding America Study were analyzed using multinomial
logistic regression. Participants reported being willing, undecided, and unwilling to get vaccinated
against COVID-19 across 13 assessments conducted from April to October 2020. Public attitudes
to vaccination against COVID-19 were also assessed on a 4-point Likert-type scale.
Results: Willingness to vaccinate declined from 71% in April to 53.6% in October. This was
explained by an increase in the percentage of participants undecided about vaccinating (from
10.5% to 14.4%) and the proportion of the sample unwilling to vaccinate (from 18.5% to 32%). The
population subgroups most likely to be undecided/unwilling to vaccinate were those without a
degree (undecided: RR=2.47, 95% CI=2.04, 3.00; unwilling: RR=1.92, 95% CI=1.67, 2.20), Black par-
ticipants (undecided: RR=2.18, 95% CI=1.73, 2.74; unwilling: RR=1.98, 95% CI=1.63, 2.42), and
female participants (undecided: RR=1.41, 95% CI=1.20, 1.65; unwilling: RR=1.29, 95% CI=1.14,
1.46). Participants who were older or were on higher incomes were least likely to be undecided or
unwilling to vaccinate. Concerns about potential side effects of a vaccine were common.
Conclusions: Intentions to be vaccinated against COVID-19 have declined rapidly during the
pandemic, and close to half of Americans are undecided or unwilling to be vaccinated.
Am J Prev Med 2021;000(000):1−8. © 2021 American Journal of Preventive Medicine. Published by Elsevier Inc.
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10.1016/j.amepre.2021.01.008As of the middle of February 2021, the coronavirusdisease 2019 (COVID-19) pandemic has beenresponsible for >2.3 million deaths worldwide.1
Vaccines against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed in
an unprecedented time, and there are now multiple
vaccines that have been shown to be effective in pre-
venting symptomatic COVID-19 infections.2 The U.S.
Food and Drug Administration (FDA) has issued
emergency use authorization for the mass roll out of
the Pfizer−BioNTech and Moderna COVID-19 vac-
cines,3 and other candidates may be approved fordistribution in the near future. However, the overall
effectiveness of any vaccine is dictated, at least in part,
by the proportion of the population willing to be vac-
cinated. Simulation studies suggest that at least three
quarters of the population may need to be vaccinated
to extinguish the ongoing COVID-19 pandemic.4,5enses/by/4.0/).
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2 Daly and Robinson / Am J Prev Med 2021;000(000):1−8During the early stages of the pandemic (March−June),
studies of small samples of European and Australian adults
suggested that the majority of surveyed people reported
that they would be vaccinated when a widely available vac-
cine was available.6,7 Similarly, a nationally representative
study of adults in China conducted in March found that
9 in 10 persons would accept a vaccine when available.8 U.
S. studies conducted early in the pandemic found that
between 58% and 86% of adults reported that they were
likely to be vaccinated against COVID-19.6,9−11
However, the rise of fake news during the pandemic has
been widely acknowledged,11,12 and widespread misinfor-
mation about the pandemic may have been damaging to
the public uptake of measures designed to reduce the
spread of the virus (e.g., mask wearing, social distancing)
and the willingness to vaccinate.10,13,14 In addition, because
the speed at which COVID-19 vaccines have been devel-
oped has been unparalleled and this has been widely
reported,2,3 this may have made the public more hesitant
about accepting a vaccine when available.15,16 Furthermore,
research indicates that in some countries, the public trust in
government handling of the COVID-19 crisis has been
affected negatively,17 and this too may have detrimentally
affected intentions to follow public health guidance.
The COVID-19 pandemic has had a disproportionately
large impact on ethnic minorities18 and groups from lower
socioeconomic backgrounds,19 and as infections will likely
continue to be socially patterned, understanding whether
population demographics determine the willingness to vac-
cinate will also be important. For example, research exam-
ining previous influenza vaccination programs has found
that vaccination intentions and uptake are reduced among
more disadvantaged groups.20,21 Initial research examining
COVID-19 vaccination intentions has produced mixed
findings on the role of demographic predictors, which may
be due to a reliance to date on relatively small and nonrep-
resentative samples.9,10,22
This study examines the estimates of the proportion
of the U.S. general population that would be willing to
use a vaccine when available. In addition, this study
examines whether the estimates of vaccination uptake
collected much earlier in the pandemic have changed
over time. Furthermore, this study seeks to understand
whether the intentions to vaccinate are socially patterned
and more or less likely in specific population subgroups.
This information will provide an empirical basis for
directing public health messages at those who are least
likely to vaccinate.15,16 To do this, this research made
use of data from the Understanding America Study
(UAS), a large nationally representative panel of U.S.
adults who have reported their vaccine intentions on 13
occasions from the outbreak of the pandemic through
October 2020.METHODS
Study Sample
This study utilized data collected as part of the UAS, a nationally
representative longitudinal study of adults aged ≥18 years. The
UAS is a probability-based sample recruited through address-
based sampling from the U.S. Postal Service Computerized Deliv-
ery Sequence file containing all U.S. postal addresses.23 Partici-
pants complete surveys online, and those without Internet access
are provided with tablet computers and Internet access. Surveys
were administered in English and Spanish, and participants were
compensated with approximately $20 for 30 minutes of survey
time.24 Of 8,547 UAS participants eligible to take part in the
COVID-19 tracking study, 7,547 participated and provided data.
The UAS COVID-19 tracking study has been utilized to examine
the changes in personal and social reactions, risk perception,25,26
and mental health27 in response to the pandemic. Vaccination
intentions were assessed in 13 of the 15 waves of the assessment
conducted every 2 weeks between April 1, 2020 and October 31,
2020.24 The number of participants and observations per survey
month are shown in Appendix Table 1 (available online). The per-
centage of participants providing willingness to vaccinate data was
lowest in June (74.1%) and relatively stable in other months (rang-
ing from 81.8% to 88.1%) (Appendix Table 1, available online).
In total, participants provided 80,060 observations across the 13
survey waves (average response rate of 81.6% among COVID-19
tracking study participants). A small portion (2%) of observations
were omitted because they were submitted after October 31 or were
missing vaccination intentions or covariate data, leaving a total of
78,453 observations (10.4 per participant). The UAS weights were
applied to adjust for unequal probabilities of selection into the UAS.
Post-stratification weights were also incorporated to provide a cor-
rection for nonresponse by aligning each survey wave with the distri-
bution of demographic characteristics of the U.S. population
(Angrisani M, Center for Economic and Social Research (CESR),
unpublished observations, 2019).
The UAS was approved by the University of Southern Califor-
nia Human Subjects Committee IRB, and informed consent was
obtained from all participants (through computer link). The May-
nooth University Social Research Ethics Sub-Committee does not
require ethical approval to be granted for the secondary use of
anonymous data, such as the data used in this study.
Measures
In each survey wave, participants indicated how likely there were to
get vaccinated for COVID-19 when a vaccine becomes available to
the public on a 5-point scale. Participants were classified as either
(1) undecided (responses of unsure), (2) unwilling to vaccinate
(responses of somewhat or very unlikely to vaccinate), or (3) willing
to vaccinate (responses of somewhat or very likely to vaccinate).
Vaccination intentions were predicted by the month of the survey
(April, May, June, July, August, September, and October) and a set
of demographic variables: age (18−34, 35−44, 50−64, ≥65 years),
sex (male, female), race/ethnicity (White, Hispanic, Black, other
race/ethnicity), household income (≤$40,000/$40,000−$100,000/
≥$100,000 gross per annum), college degree (versus none), and the
presence of a chronic health condition (present versus not present).
Specifically, participants indicated whether they had been diagnosed
with the following conditions: diabetes, cancer, heart disease, kidney
disease, asthma, chronic lung disease, or an autoimmune disease.www.ajpmonline.org
Table 1. Attitudes Toward Vaccination Against COVID-19 in the Understanding America Study Assessed Between October 14,
2020 and October 31, 2020 (N=5,762)





Questiona Agree (%) Disagree (%) Agree (%) Disagree (%) Agree (%) Disagree (%) Agree (%) Disagree (%)
The COVID vaccine will be
important for my health.
71.2 28.8 93.8 6.2 69.1 30.9 33.7 66.3
Getting a COVID vaccine
would be a good way to
protect me from
coronavirus disease.
74.2 25.8 95.4 4.6 71.6 28.4 39.3 60.7
The COVID vaccine will be
effective if it is approved
by the FDA or CDC.
73.7 26.3 92.4 7.6 71.0 29.0 43.1 56.9
Getting the COVID vaccine
will be important for the
health of others in my
community.
79.4 20.6 96.1 3.9 77.7 22.3 51.7 48.3
The COVID vaccine will be
beneficial to me.
73.8 26.2 95.1 4.9 74.3 25.7 37.4 62.6




74.5 25.5 92.8 7.2 70.9 29.1 44.7 55.3
The COVID vaccine will not
be around long enough to
be sure it is safe.
48.1 51.9 39.9 60.1 58.8 41.2 57.3 42.7
I am concerned about
serious side effects of the
COVID vaccine.
69.7 30.3 60.6 39.4 81.4 18.6 80.2 19.8
I think the COVID vaccine
might cause lasting health
problems for me.
43.6 56.4 26.6 73.4 61.5 38.5 65.0 35.0
Note: Estimates are based on weighted data.
aEach item was rated on a 4-point scale, with those responding Somewhat or Strongly agree coded as Agree and those responding Somewhat or
Strongly disagree coded as Disagree.
bBased on responses to the question: How likely are you to get vaccinated for coronavirus once a vaccine is available to the public? In this survey
wave (responses between October 14, 2020 and October 31, 2020), 54% of the sample were classified as willing to vaccinate, 14% were classified
as undecided, and 32% were classified as unwilling to vaccinate.
CDC, Centers for Disease Control and Prevention; FDA, U.S. Food and Drug Administration.
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1=strongly disagree to 4=strongly agree), with 9 items assessing
their attitudes toward a potential vaccine (Table 1 provides items
in full) in late October (October 14‒31). Questions assessed the
participant’s beliefs that the COVID-19 vaccine would be benefi-
cial, important for personal and community health, and a good
way to protect from COVID-19. Participants also indicated
whether they agreed that approved vaccines would be effective
and whether they were concerned about the lack of long-term fol-
low-up information, and potential side effects of a COVID-19
vaccine were assessed (e.g., I think the COVID-19 vaccine might
cause lasting health problems for me).Statistical Analysis
First, investigators examined the trends in vaccination intentions
over the period of the study by comparing the prevalence of will-
ingness/being undecided/unwillingness to vaccinate in April and& 2021October 2020. To estimate the statistical significance of time
trends, multinomial logistic regression analysis28 was used with
robust SEs clustered at the individual level. Those willing to vacci-
nate were compared with (1) those undecided on vaccination and
(2) those unwilling to vaccinate. A series of multinomial logistic
regressions were run to identify whether the relative risk (RR) of
being undecided or unwilling to vaccinate increased from April to
October for the overall sample and for each examined population
subgroup. This model contrasts the natural log (Probability [Pr]
[unwilling to vaccinate]/Pr[willing to vaccinate]) and the natural
log (Pr[undecided on vaccination]/Pr[willing to vaccinate]) esti-
mates across different demographic groups to ascertain relative
risk ratios (RRRs).
Next, multinomial logistic regression was used to estimate the
extent to which survey month and different demographic factors
predicted vaccination intentions. A single adjusted analysis was
used to estimate the independent effect of each predictor variable
(i.e., month of the survey, age, sex, race/ethnicity, educational
ARTICLE IN PRESS
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for all others. In addition, the authors tested a separate model
where interactions between survey month and participant demo-
graphics were added to the main model to test whether changes in
vaccination intentions over time differed systematically between
demographic groups. Finally, in a supplementary sensitivity anal-
ysis, the willingness to vaccinate was treated as a continuous out-
come (ranging from 1=very likely to vaccinate to 5=very unlikely
to vaccinate) examined using ordinary least squares regression
with SEs clustered at the individual level.
All analyses incorporated the UAS sampling weights to gener-
ate nationally representative estimates. RRRs and 95% CIs were
estimated using the Stata, version 15.RESULTS
Participants were aged 47.2 (SD=16.6) years on average;




Variables Sample size (%) % %
Overall sample 71.0 53.6
Age group, years
18‒34 2,024 (26.8) 65.6 47.2
35‒49 2,305 (30.5) 67.5 49.6
50‒64 1,832 (24.3) 73.1 54.2
≥65 1,386 (18.4) 79.9 65.9
Sex
Male 3,613 (47.9) 75.1 60.0
Female 3,934 (52.1) 67.2 47.6
Race/ethnicity
White 4,840 (64.1) 74.7 57.3
Hispanic 1,345 (17.8) 67.4 47.5
Black 917 (12.2) 47.9 33.8
Other race/ethnicity 445 (5.9) 86.5 68.6
Education
No degree 4,969 (65.8) 65.7 45.1
College degree 2,578 (34.2) 81.4 68.9
Income levelb
Low income 2,884 (38.2) 64.1 43.6
Middle income 3,007 (40.4) 71.6 55.0
High incomeb 1,656 (21.9) 81.1 66.9
Chronic conditionc
No 5,060 (67.0) 69.5 52.5
Yes 2,446 (32.4) 74.1 55.8
Note:Weighted demographic characteristics and vaccination intentions are p
aBased on responses to the question: How likely are you to get vaccinated fo
bHouseholds earning <$40,000 a year were classified as low income, thos
those above this threshold were classified as high income.
cDiagnosed with any of the following: diabetes, cancer, heart disease, kidne
A total of 41 participants did not provide chronic illness data and were includ
Obs., observations; UAS, Understanding America Study.and 64.1% were White, 17.8% were Hispanic, 12.2%
were Black, and 5.9% were Other race/ethnicity (Table 2).
On average, willingness to vaccinate declined from 71%
in April to 53.6% in October. This was explained by an
increase in the percentage of participants undecided
about vaccinating against COVID-19 (from 10.5% to
14.4%) and the portion of the sample unwilling to vacci-
nate (from 18.5% to 32%) (Table 2). A decrease in the
willingness to vaccinate against COVID-19 between
April and October was evident across all examined pop-
ulation subgroups (Table 2).
An unadjusted multinomial logistic regression anal-
ysis confirmed that from April to October 2020, there
was a statistically significant higher risk of being unde-
cided (RRR=1.82, 95% CI=1.62, 2.05) or unwilling
(RRR=2.29, 95% CI=2.11, 2.48) to be vaccinated than
being willing to get vaccinated (Appendix Table 2,,547, Obs.=78,453) and Vaccination Intentions in April and
Undecided on vaccinationa Unwilling to vaccinatea
April, October, April, October,
% % % %
10.5 14.4 18.5 32.0
12.9 16.2 21.5 36.6
11.5 15.5 21.0 34.9
10.6 15.1 16.3 30.7
6.0 10.0 14.1 24.0
8.2 11.7 16.7 28.3
12.7 17.0 20.1 35.4
8.6 13.0 16.7 29.7
12.2 16.2 20.5 36.3
22.0 21.8 30.1 44.3
4.0 11.1 9.5 20.4
13.1 18.2 21.2 36.7
5.4 7.8 13.2 23.4
15.6 21.4 20.3 35.0
8.6 12.1 19.8 33.0
5.6 7.8 13.3 25.4
10.6 14.2 19.9 33.4
10.3 14.9 15.6 29.2
resented.
r coronavirus once a vaccine is available to the public?
e earning $40,000‒$100,000 were classified as middle income, and
y disease, asthma, chronic lung disease, and an autoimmune disease.
ed using a missing data dummy.
www.ajpmonline.org
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regression analyses also showed that all population
subgroups were more likely to be undecided or unwill-
ing to vaccinate in October than in April (Appendix
Table 2, available online). There was also a greater
than 2-fold higher relative likelihood of being unde-
cided or unwilling to get the COVID-19 vaccine in
October than in April 2020 (undecided: RRR=2.03,
95% CI=1.79, 2.29; unwilling: RRR=2.47, 95%
CI=2.27, 2.68) in a fully adjusted model that included
controls for participant demographic factors and the
presence of chronic illness (Table 3). An examinationTable 3. Results of the Adjusted Multinomial Logistic
Regression Analyses Examining Demographic Predictors
and Temporal Changes in Indecision and Unwillingness to







RRRa (95% CI) RRRa (95% CI)
Month (ref=April)
May 1.27*** (1.15, 1.41) 1.54*** (1.44, 1.66)
June 1.34*** (1.18, 1.52) 1.65*** (1.51, 1.80)
July 1.47*** (1.30, 1.67) 1.76*** (1.62, 1.91)
August 1.50*** (1.33, 1.68) 1.97*** (1.82, 2.13)
September 1.92*** (1.70, 2.16) 2.34*** (2.16, 2.55)
October 2.03*** (1.79, 2.29) 2.47*** (2.27, 2.68)
Age group, years (ref=18‒34)
35‒49 1.07 (0.87, 1.33) 1.02 (0.85, 1.21)
50‒64 0.88 (0.71, 1.09) 0.81* (0.68, 0.97)
≥65 0.49*** (0.38, 0.63) 0.61*** (0.51, 0.74)
Sex (ref=male)
Female 1.41*** (1.20, 1.65) 1.29*** (1.14, 1.46)
Race/ethnicity (ref=White)
Hispanic 1.05 (0.82, 1.35) 1.02 (0.84, 1.25)
Black 2.18*** (1.73, 2.74) 1.98*** (1.63, 2.42)
Other race/ethnicity 0.57** (0.40, 0.82) 0.52*** (0.39, 0.71)
Education (ref=degree)
No degree 2.47*** (2.04, 3.00) 1.92*** (1.67, 2.20)
Income level (ref=low income)b
Middle income 0.58*** (0.48, 0.69) 1.01 (0.88, 1.16)
High income 0.40*** (0.32, 0.50) 0.75** (0.63, 0.90)
Chronic conditionc 0.96 (0.81, 1.14) 0.84* (0.74, 0.96)
Note: Boldface indicates statistical significance (*p<0.05, **p<0.01,
***p<0.001).
aEstimates are RRRs derived from multinomial logistic regression with
SEs adjusted for clustering at the individual level and controlling for all
characteristics presented. For all analyses, willing to vaccinate was the
outcome reference group.
bHouseholds earning <$40,000 a year were classified as low income,
those earning $40,000‒$100,000 were classified as middle income,
and those above this threshold were classified as high income.
cDiagnosed with any of the following: diabetes, cancer, heart dis-
ease, kidney disease, asthma, chronic lung disease, and an auto-
immune disease.
Obs., observations.
& 2021of month-to-month changes confirmed that the likeli-
hood of being undecided or unwilling to vaccinate
(versus being willing to vaccinate) increased from
April to October (Table 3 and Figure 1).
When all observations from the 13 survey waves
were examined, those without a college degree were at
elevated risk of being undecided or unwilling to vacci-
nate (undecided: RRR=2.47, 95% CI=2.04, 3.00;
unwilling: RRR=1.92, 95% CI=1.67, 2.20), as were
Black participants (undecided: RRR=2.18, 95%
CI=1.73, 2.74; unwilling: RRR=1.98, 95% CI=1.63,
2.42) and female participants (undecided: RRR=1.41,
95% CI=1.20, 1.65; unwilling: RRR=1.29, 95%
CI=1.14, 1.46). By contrast, a reduced risk of being
undecided or unwilling to vaccinate was found among
those aged ≥65 years (undecided: RRR=0.49, 95%
CI=0.38, 0.63; unwilling: RRR=0.61, 95% CI=0.51,
0.74), those on high household incomes (undecided:
RRR=0.40, 95% CI=0.32, 0.50; unwilling: RRR=0.75,
95% CI=0.63, 0.90), and other race/ethnicity partici-
pants (undecided: RRR=0.57, 95% CI=0.40, 0.82;
unwilling: RRR=0.52, 95% CI=0.39, 0.71).
An examination of the interactions between survey
month and individual demographic characteristics did
not yield evidence for systematic differences in changes
in vaccination intentions over time between demo-
graphic groups. Furthermore, very similar associations
were identified in a sensitivity analysis where willingness
to vaccinate was treated as a continuous variable
(Appendix Table 3, available online).
Finally, this study examined the attitudes toward the
vaccine reported between October 14 and 31, 2020. The
majority of the sample (70%−80%) agreed that the
COVID-19 vaccine would be personally beneficial, impor-
tant for personal and community health, a good way to
protect from COVID-19, and effective if approved by
FDA or the Centers for Disease Control and Prevention
(Table 1). However, responses differed markedly between
those willing and those unwilling to be vaccinated. For
example, whereas 92.4% of those who were willing to be
vaccinated agreed that the vaccine would be effective if
approved by FDA or Centers for Disease Control and Pre-
vention, only 43.1% of those unwilling to be vaccinated
agreed. In the overall sample, it was common for partici-
pants to report concerns over the vaccine, and 69.7%
agreed that they were concerned about serious side effects
of the vaccine. In total, 44% agreed that the vaccine might
cause lasting health problems for them. However, such
concerns were more prevalent among those unwilling to
be vaccinated. For example, 65% of those unwilling to be
vaccinated were concerned about lasting health problems
resulting from the vaccine compared with 26.6% of those
willing to be vaccinated.
Figure 1. Change in vaccination intentions across the 13 waves of the Understanding America Study conducted between April 1,
2020 and October 31, 2020.
Note: Graph is based on an analysis of 78,453 observations on 7,547 participants. Estimates are predicted probabilities from the marginal effects
calculated after a multinomial logistic regression model adjusted for age, sex, race/ethnicity, household income, educational attainment, and the
presence of pre-existing health conditions. 95% CIs are presented in gray.
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In a large nationally representative sample of U.S. adults,
intentions to be vaccinated against COVID-19 have
declined from a high of 71% of the population in April
2020 to close to only 54% reporting being willing to vac-
cinate in October 2020. Reporting being undecided or
unwilling to vaccinate was more likely among those with
lower levels of education and income as well as in
female, Black (African American), and younger adults.
Concerns about the vaccine causing long-lasting health
problems and uncertainty about the benefits of the vaccine
were also common.
On the basis of the estimates that vaccination cover-
age of close to 75% may be required to vaccinate to erad-
icate COVID-19 ,4,5,10,29 the present estimates that are
close to 50% of the population may be willing to vacci-
nate are concerning. It will now be critical to better
understand the reasons why a large proportion of the
population are skeptical about vaccination against
COVID-19. Public concerns about the safety of vaccines
may be an important driver of the increase in the pro-
portion of the population reporting being unsure or
explicitly stating that they will not vaccinate.10
In line with this, 70% of this study sample reported
being concerned about serious side effects of the vaccine,
and 44% believed that a vaccine might cause lasting
health problems for them. To some extent, these con-
cerns are to be expected given the unprecedented speed
at which vaccines have been developed.2,3 However, the
rise of anti-vaccination misinformation (e.g., misleading
healthcare information, conspiracy theories) andpolitical polarization may also have played a role in
explaining this increase.11−1429 It will therefore be criti-
cal that accurate safety information is widely and trans-
parently communicated by trusted sources to promote
confidence in the scientific decision making underpin-
ning the approval of COVID-19 vaccines.16,21
It will also be important to address social inequalities
in vaccination intentions20,21 and to ensure widespread
uptake of effective COVID-19 vaccines. In this study,
willingness to vaccinate was strikingly lower among
more disadvantaged groups (e.g., African Americans
and those with lower income and education levels), and
these groups have already been disproportionately
affected by COVID-19.18,19 Previous research on influ-
enza vaccines also suggests that access issues may pre-
vent minority and disadvantaged groups from being
vaccinated.21,30 It will therefore be important to identify
the strategies to reduce social inequalities in both vacci-
nation intentions and opportunities to vaccinate.20
The strengths of this research include the use of a large
probability-based nationally representative sample of
adults, allowing generalizations to be made to the popula-
tion. This study also moves beyond previous research6−10
by including a high-frequency longitudinal assessment of
vaccination intentions throughout the pandemic. In addi-
tion, participant concerns and perceptions of the benefits
of a potential vaccine were assessed to shed light on
potential reasons for the low willingness to vaccinate.
Limitations
A limitation of the UAS is the potential lack of represen-
tation of those who do not speak either English orwww.ajpmonline.org
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surveys. In addition, this study is limited in its reliance
on self-reported intentions about a hypothetical vaccine
and the lack of detailed assessment of factors that may
explain why vaccination intentions have declined over
time in the U.S. However, in advance of the deployment
of a COVID-19 vaccine, it has been necessary to rely on
intention-based measures that have been shown to pre-
dict vaccination behavior.30 Furthermore, intentions are
malleable and represent a target for evidence-based
approaches aiming to increase the proportion of the
population who are willing to vaccinate.31 This now rep-
resents an urgent public health priority to minimize fur-
ther loss of life due to the COVID-19 pandemic. It is
also essential that research aiming to modify vaccination
uptake is theory based and informed by relevant models
such as the Health Belief Model,32 which provides a
framework for understanding the factors that may shape
vaccination intentions (e.g., perceived benefits and bar-
riers, perceived susceptibility to COVID-19) and future
behavior.
Finally, now that vaccines are authorized and informa-
tion on their effectiveness and safety is available, it is crucial
that studies track vaccination attitudes (e.g., perceived
health benefits and side effects, social norms relating to
vaccination) to provide an in-depth understanding of how
vaccine intentions and uptake change as vaccines are
deployed. Initial research suggests that willingness to vacci-
nate may have increased in November when the availability
of viable vaccines appeared imminent.33CONCLUSIONS
Intentions to be vaccinated against COVID-19 have
declined rapidly during the pandemic, and in October
2020, close to half of Americans were undecided or
unwilling to be vaccinated. This reduced willingness to
vaccinate may undermine the pandemic response and
the public health benefits of an effective vaccine.ACKNOWLEDGMENTS
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